Drug intelligence / Profile preview

GB-4362

Development stage: Phase 1
Lead developer: Generate Biomedicines
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

GB-4362 is a systemically administered monoclonal antibody developed by Generate Biomedicines using its AI-powered generative protein design platform. It is designed to selectively bind and neutralize free monomethyl auristatin E (MMAE), a potent cytotoxic payload frequently used in antibody-drug conjugates (ADCs). By sequestering free MMAE released into the systemic circulation, GB-4362 aims to reduce payload-mediated toxicities, such as peripheral neuropathy and neutropenia, thereby improving the therapeutic index of MMAE-based ADCs. It is intended as an adjunctive therapy to be used in combination with ADCs like enfortumab vedotin to preserve anti-tumor activity while mitigating systemic side effects.

Targets

Microtubule

Beyond the preview

Go deeper on GB-4362.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GB-4362.

Explore the full profile